Selinexor, a First-in-Class XPO1 Inhibitor, Is Efficacious and Tolerable in Patients with Myelodysplastic Syndromes Refractory to Hypomethylating Agents

Overview of attention for article published in Blood, November 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (78th percentile)
Good Attention Score compared to outputs of the same age and source (74th percentile)

Mentioned by

blogs: 1 blog

twitter: 1 X user

Readers on

mendeley: 5 Mendeley

So far, Altmetric has seen 1 X post from an account with 3,705 followers.

@mtmdphd @chadinabhan @myelomaMD @Rfonsi1 @DrOlaLandgren @Myeloma_Doc @VincentRK @HenrychihangFu1 @BldCancerDoc I agree. We used this in a clinical trial in R/R #MDS and found 32% response rate with 60mg twice weekly (dose in RRMM is 80mg twice weekly),…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.

Login to access the Sentiment Analysis related to this output.